Copyright
©2014 Baishideng Publishing Group Co.
World J Gastroenterol. Feb 28, 2014; 20(8): 2098-2106
Published online Feb 28, 2014. doi: 10.3748/wjg.v20.i8.2098
Published online Feb 28, 2014. doi: 10.3748/wjg.v20.i8.2098
Marker | ER group | NER group | P value | Overall survival | P value | ||
n = 25 | n = 25 | 1 yr | 2 yr | 3 yr | |||
CD133 | |||||||
Positive | 20 | 22 | 0.440 | 85.9% | 71.2% | 68.6% | 0.732 |
Negative | 5 | 3 | 87.5% | 72.9% | 54.7% | ||
CD90 | |||||||
Positive | 22 | 11 | 0.001 | 78.8% | 60.2% | 56.4% | 0.018 |
Negative | 3 | 14 | 100.0% | 94.1% | 88.2% | ||
EpCAM | |||||||
Positive | 14 | 7 | 0.045 | 85.7% | 51.3% | 46.2% | 0.010 |
Negative | 11 | 18 | 86.2% | 86.2% | 82.3% |
- Citation: Guo Z, Li LQ, Jiang JH, Ou C, Zeng LX, Xiang BD. Cancer stem cell markers correlate with early recurrence and survival in hepatocellular carcinoma. World J Gastroenterol 2014; 20(8): 2098-2106
- URL: https://www.wjgnet.com/1007-9327/full/v20/i8/2098.htm
- DOI: https://dx.doi.org/10.3748/wjg.v20.i8.2098